TransMedics Group, Inc. (TMDX) SEC Filings
Filing links are provided when reliable SEC filing data is available.
Recent Filings
| Form | Filing Date | Accepted | Document |
|---|---|---|---|
| 4 | Jun 17, 2026 | Jun 17, 2026 | View filing |
| SD | May 29, 2026 | May 29, 2026 | View filing |
| 4 | May 22, 2026 | May 22, 2026 | View filing |
| 4 | May 22, 2026 | May 22, 2026 | View filing |
| 4 | May 22, 2026 | May 22, 2026 | View filing |
| 4 | May 22, 2026 | May 22, 2026 | View filing |
| 4 | May 22, 2026 | May 22, 2026 | View filing |
| 4 | May 22, 2026 | May 22, 2026 | View filing |
| 4 | May 22, 2026 | May 22, 2026 | View filing |
| 4 | May 21, 2026 | May 21, 2026 | View filing |
| 8-K | May 21, 2026 | May 21, 2026 | View filing |
| DEFA14A | May 7, 2026 | May 7, 2026 | View filing |
| 10-Q | May 5, 2026 | May 5, 2026 | View filing |
| 8-K | May 5, 2026 | May 5, 2026 | View filing |
| SC 13G | Apr 30, 2026 | Apr 30, 2026 | View filing |
| SC 13G | Apr 29, 2026 | Apr 29, 2026 | View filing |
| ARS | Apr 10, 2026 | Apr 10, 2026 | View filing |
| DEFA14A | Apr 10, 2026 | Apr 10, 2026 | View filing |
| DEF 14A | Apr 10, 2026 | Apr 10, 2026 | View filing |
| SC 13G/A | Mar 27, 2026 | Mar 27, 2026 | View filing |
| 3 | Mar 13, 2026 | Mar 13, 2026 | View filing |
| 4 | Mar 6, 2026 | Mar 6, 2026 | View filing |
| 4 | Mar 6, 2026 | Mar 6, 2026 | View filing |
| 4 | Mar 4, 2026 | Mar 4, 2026 | View filing |
| 144 | Mar 4, 2026 | Mar 4, 2026 | View filing |
| 144 | Mar 4, 2026 | Mar 4, 2026 | View filing |
| 144 | Mar 4, 2026 | Mar 4, 2026 | View filing |
| 4 | Mar 4, 2026 | Mar 4, 2026 | View filing |
| 4 | Mar 4, 2026 | Mar 4, 2026 | View filing |
| 8-K | Feb 27, 2026 | Feb 27, 2026 | View filing |
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein